Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 09/19/22
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This YearInvestors Business Daily • 09/19/22
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common StockGlobeNewsWire • 09/15/22
Akero Therapeutics Wows Investors With Unexpected Win For Hepatitis TreatmentInvestors Business Daily • 09/13/22
In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 WeeksGlobeNewsWire • 09/13/22
Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASHGlobeNewsWire • 09/08/22
Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of TreatmentGlobeNewsWire • 08/24/22
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/22
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH FibrosisGlobeNewsWire • 06/27/22
Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap BiopharmaBenzinga • 06/16/22
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 MillionGlobeNewsWire • 06/16/22
Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASHGlobeNewsWire • 06/13/22
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/25/22